Gene · 80339
Papers3,957
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,957
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients. | J Liver Cancer | 2026 | 41340406 | PubTator, text mining | PubMed |
| Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia. | Hepatol Res | 2026 | 41307922 | PubTator, text mining | PubMed |
| Sugar Rationing in the First 1000 Days After Conception and Long-Term Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Major Adverse Liver Outcomes: A Natural Experiment Study. | Clin Gastroenterol Hepatol | 2026 | 41284512 | PubTator, text mining | PubMed |
| Bridging the variant-to-function gap in type 2 diabetes: advances and challenges. | Diabetologia | 2026 | 41273414 | PubTator, text mining | PubMed |
| Acute Alcoholic Hepatitis: New and Experimental Medications. | Clin Liver Dis | 2026 | 41266021 | PubTator, text mining | PubMed |
| TWAS atlas 2.0: an updated data resource for transcriptome-wide association studies. | Nucleic Acids Res | 2026 | 41251136 | PubTator, text mining | PubMed |
Associations between per- and polyfluoroalkyl substances and metabolic dysfunction-associated steatotic liver disease in adolescents and young adults: modifying roles of age, lifestyle factors, and PNPLA3 genotype. | Environ Res | 2026 | 41232903 | PubTator, text mining | PubMed |
| Genetic Analysis of Metabolic-associated Steatosis Liver Disease in a Colombian Cohort. | J Clin Exp Hepatol | 2026 | 41210107 | PubTator, text mining | PubMed |
| Human iPSC Models Reveal PNPLA3 Variant-Specific Lipid Pathways: Implications for Targeted Therapy in NAFLD. | J Gastroenterol Hepatol | 2026 | 41199137 | PubTator, text mining | PubMed |
| The IUPHAR/BPS Guide to PHARMACOLOGY in 2026. | Nucleic Acids Res | 2026 | 41160876 | PubTator, text mining | PubMed |
| Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Aliment Pharmacol Ther | 2026 | 41147688 | PubTator, text mining | PubMed |
| Gut microbiota-mediated oncogenesis in hepatocellular carcinoma: a new avenue for therapeutic intervention. | Int J Surg | 2026 | 41143647 | PubTator, text mining | PubMed |
| Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH. | Ann Hepatol | 2026 | 41135761 | PubTator, text mining | PubMed |
| Association between long-term exposure to PM10 and metabolic dysfunction-associated steatotic liver disease (MASLD) in subjects with disturbed metabolic homeostasis and genotypes at risk. | Eur J Intern Med | 2026 | 41111036 | PubTator, text mining | PubMed |
| Genetic and non-genetic drivers of histological progression and regression in MASLD. | J Hepatol | 2026 | 40998180 | PubTator, text mining | PubMed |
| Evaluation of PNPLA3 genetic variants in Egyptian HBV-infected patients concomitant with metabolic-associated steatotic liver disease (MASLD). | Diagn Microbiol Infect Dis | 2026 | 40976057 | PubTator, text mining | PubMed |
| MAFLD: a ferroptotic disease. | Trends Mol Med | 2026 | 40930855 | PubTator, text mining | PubMed |
| Biological Age, PNPLA3, and Risk of Metabolic Dysfunction-associated Steatotic Liver Disease. | Clin Gastroenterol Hepatol | 2026 | 40865626 | PubTator, text mining | PubMed |
| Genetic variants underlying precancerous conditions of hepatocellular carcinoma. | Int J Cancer | 2026 | 40833357 | PubTator, text mining | PubMed |
| Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk. | Curr Pharm Des | 2026 | 40192053 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/80339/papers?page=9